Methods for producing an immune response to tuberculosis

Details Methods for producing an immune response to tuberculosis Methods for producing an immune response to tuberculosis

2007-03-14

2010-11-30

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S185100, C424S190100, C424S193100, C424S197110, C424S234100

Reexamination Certificate

active

07842299

ABSTRACT:
Methods for producing an immune response toMycobacterium tuberculosis(Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of tuberculosis are also disclosed.

REFERENCES:
patent: 6294328 (2001-09-01), Fleischmann et al.
patent: 6384018 (2002-05-01), Content et al.
patent: 6555653 (2003-04-01), Alderson et al.
patent: 7074559 (2006-07-01), Kapur et al.
patent: 7332340 (2008-02-01), Tyagi et al.
patent: 7424370 (2008-09-01), Sachdeva et al.
patent: 7510718 (2009-03-01), Krohn et al.
patent: 2002/0176867 (2002-11-01), Andersen et al.
patent: 2002/0192229 (2002-12-01), Flyer et al.
patent: 2003/0147897 (2003-08-01), Andersen et al.
patent: 2004/0057963 (2004-03-01), Andersen et al.
patent: 2004/0141985 (2004-07-01), Lalvani et al.
patent: 2005/0123511 (2005-06-01), McCreavy et al.
patent: 2005/0288866 (2005-12-01), Sachdeva et al.
patent: 2007/0042383 (2007-02-01), Kapur et al.
patent: 2008/0124549 (2008-05-01), Lee et al.
patent: 2009/0070897 (2009-03-01), Goldman et al.
patent: 2009/0324503 (2009-12-01), Lewinsohn et al.
patent: 2010/0129391 (2010-05-01), Reed et al.
patent: 1 484 405 (2004-12-01), None
patent: WO 98/53075 (1998-11-01), None
patent: WO 99/24577 (1999-05-01), None
patent: WO 99/24577 (1999-05-01), None
patent: WO 01/62893 (2001-08-01), None
patent: WO 01/74130 (2001-10-01), None
patent: WO 2007/106536 (2007-09-01), None
patent: WO 2007/106560 (2007-09-01), None
patent: WO 2009/039854 (2009-04-01), None
patent: WO 2010/034007 (2010-03-01), None
Garnier et al, PNAS, USA, 2003, 100:7877-7882.
Li et al, PNAS, USA, 2005, 102:12344-12349.
Seki et al, Vaccine, 2009, 27:1710-1716.
Stinear et al, Genome Research, 2008, 18:729-741.
Stinear et al, Genome Research, 2007, 17:192-200.
Camus et al, Microbiology, Oct. 2002, 148(Pt. 10):2967-2973.
Lewinsohn et al, PLoS Pathology, Sep. 21, 2007, 3/9:1240-1249.
Lewinsohn et al, Int. J. Tuberc. Lung Dis., 2004, 8/5:658-674.
Ellner, CTS Journal, 2008, 2/1:80-84.
Blythe et al, Immunome Research, 2007, 3:10, 14 pages.
Kawamura, Kekkaku, Nov. 2006, 81/11:687-691 abstract only.
Delogu et al, J. Infection in Developing Countries, 2009, 3/1:5-15 abstract only.
Ottenhoff, Eur. J. Immunol., 2009, 39:2014-2020.
Doherty et al, Expert Opin. Biol. Ther., 2007, 7/10:1539-1549.
Gupta et al, Vaccine, 2007, 25:3742-3751.
Braibant et al, FEMS Microbiol. Rev., 2000, 24/4:449-467.
Sassetti et al, Mol. Microbiol., 2003, 48/1:77-84.
Rengarajan et a, PNAS, USA, 2005, 102:8327-8332.
Ottenhoff et al, In: Handbook of Tuberculosis: Immunology and Cell Biology, 2008, eds. Kaufman et al, pp. 119-155 abstract only.
Cole et al, Nature, 1998, 393:537-544.
Brosch et al, PNAS, USA, 2007, 104:5596-5601.
Greenspan et al, Nature Biotechnology, 1999, 7:936-937.
Burgess et al, JCB, 1990, 111:2129-2138.
Lazar et al, Molecular and Cellular Biology, 1988, 8:1247-1252.
Creighton, In: Proteins: Structures and Molecular Properties, 1984, pp. 314-315.
Houghten et al, Vaccine 86, 1986, pp. 21-25.
Bixler et al, Synthetic Vaccines, vol. 1, 1987, pp. 39-71.
Bowie et al, Science, 1990, 247:1306-1310.
Kumar et al, PNAS, Feb. 1991, 87:1337-1341.
Creighton, In: Protein Structure: A Practical Approach, 1989, pp. 184-186.
Nosoh et al, In: Protein Stability and Stabilization through Protein Engineering, 1991, pp. 197-217.
Berzofsky et al, J. Clin. Invest., 2004, 113:1515-1525.
Restifo et al, Gene Therapy, 2000, 7:89-92.
Gura, Science, 1997, 278:1041-1042.
Steinman et al, Science, 2004, 305:197-200.
Fleishmann et al., “Whole-Genome Comparison ofMycobacterium tuberculosisClinical and Laboratory Strains,”Journal of Bacteriology, 184(19):5479-5490, (Oct. 2002).
Fleishmann et al., Whole genome comparison ofMycobacterium tuberculosisclinical and laboratory strains, Entry C137—MYCTU,EMBL, (2002).
Grotzke and Lewinsohn, “Role of CD8+ T lymphocytes in control ofMycobacterium tuberculosisinfection,”Microbes and Infection, 7(4):776-788, (Apr. 4, 2005).
International Search report for PCT Application No. PCT/US2007/006534; 6 pp., (Oct. 2, 2007).
International Search report for PCT Application No. PCT/US2007/006472; 7 pp., (Nov. 23, 2007).
Lewinsohn, David et al., “Characterization of Human CD8+T Cells Reactive withMycobacterium tuberculosis-infected Antigen-presenting Cells,”Journal of Experimental Medicine, 187(10):1633-1640, (May 18, 1998).
Lewinsohn, Deborah et al., “Human Dendritic Cells Presenting Adenovirally Expressed Antigen ElicitMycobacterium tuberculosis-Specific CD8+ T Cells,” American Journal of Respiratory and Critical Care Medicine, 166(6):843-848, (Sep. 15, 2002).
Smith et al., “Human CD8+CTL Specific for the Mycobacterial Major Secreted Antigen 85A,”Journal of Immunology, 165:7088-7095, (2000).
Arend et al., “Antigentic Equivalence of Human T-Cell Responses toMycobacterium tuberculosis-Specific RDI-Encoded Protein Antigens ESAT-6 and Culture Filtrate Protein 10 and to Mixtures of Synthetic Peptides,”Infection and Immunity68(6):3314-3321 (Jun. 2000).
Database Accession No. P0A4W4, “Uncharacterized ABC Transporter ATP-Binding Protein Rv1273c/MT1311,” 3pp. (Mar. 2005).
Grotzke et al., “Role of CD8+ T lymphocytes in Control ofMycobacterium tuberculosisInfection,”Microbes and Infection7:776-788 (2005).

Affiliated with

Also associated with

Rating

Methods for producing an immune response to tuberculosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for producing an immune response to tuberculosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for producing an immune response to tuberculosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4251635